A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients With Refractory Hematologic Malignancies
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-06-0511
Full Text
Open PDFAbstract
Available in full text
Date
August 1, 2006
Authors
Publisher
American Association for Cancer Research (AACR)